celg neutral surpris
messag celg report earn includ top bottom line
estim beat see earn preview celg minor miss howev
includ anoth otezla revenu dip well primari endpoint failur phase
robust trial evalu abc-subtyp dlbcl adjust
estim reflect financi result
top bottom line beat guidanc re-affirmed total revenu
line consensu vs consensu grow vs manag
attribut growth increas demand market share durat therapi across
revenu driver revlimid pomalyst otezla abraxan note otezla significantli
miss street consensu think mostli due step-up manufactur
liabil patient medicar part coverag gap doughnut
hole highlight recent preview celg maintain guidanc
alreadi account effect celg report net incom
consensu estim strong margin drove increas dilut ep
higher estim higher street estim
pipelin timelin larg track celg confirm timelin follow upcom
luspatercept mma submiss track april
liso-cel bla submiss track
fedratinib myelofibrosi pdufa date septemb
fedratinib mma submiss push year end previous guid
revlimid rituximab r/r indol non-hodgkin lymphoma pdufa date june
phase robust trial fail meet primari endpoint recal
revlimid r-chop regimen evalu phase robust
trial treatment frontlin activ b-cell subtyp dlbcl studi
initi pool result two phase ii trial show although
fail show superior r-chop overal dlbcl patient popul
increas surviv benefit among cohort patient histor
wors respons rate thu prognos interestingli similar potenti efficaci signal
among patient observ ibrutinib r-chop combin
ultim fail show superior r-chop recent phase phoenix trial
well although ir-chop show superior among younger patient year old
sever upcom present highlight detail recent
planner link celg present numer pipelin updat american
societi clinic oncolog meet host chicago il celg
highlight particular includ first clinic look celmod iberdomid
on-going phase i/ii trial r/r multipl myeloma updat liso-cel data
on-going phase trial chronic lymphocyt leukemia cll full data readout
recent fail phase apact trial evalu abraxan adjuv therapi surgic
page analyst certif import disclosur
valu celg use discount cash flow analysi util wacc termin
growth rate valu commerci product select upcom pipelin asset use sum-of-
the-part method valu celg whole
upsid risk rate valuat celg includ celg obtain higher acquisit offer bmi
share price increas current close price given share-bas compon propos
acquisit potenti faster regulatori approv expect investor three ozanimod liso-
cel would increas present valu cvr
downsid risk valuat includ bmi share price declin current close price
page analyst certif import disclosur
amort acquir intang asset
acquisition-rel charg restructur
total cost expens
interest invest incom net
compani report guggenheim secur llc estim
page analyst certif import disclosur
sg product sale
 revenu
cog product sale
soe sg
compani report guggenheim secur llc estim
page analyst certif import disclosur
cash equival
properti plant equip net
short-term borrow current portion long-term debt
accru expens current liabil
long-term debt net discount
compani report guggenheim secur llc estim
page analyst certif import disclosur
chang
flow oper
account payabl oper liabil
flow invest activ
increase/decreas secur intang fin asset
flow financ activ
payment treasuri share
net payment/proce show term borrow
proce long term debt issu
princip repay current portion long-term debt
effect currenc rate chang cash cash equival
compani report guggenheim secur llc estim
page analyst certif import disclosur
